Cargando…
Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase
Treatment of infections caused by multidrug-resistant Pseudomonas species is difficult because few antibiotics active against such organisms are available. Arbekacin, a relatively new aminoglycoside, is effective against Pseudomonas spp. in vitro. However, no clinical report on arbekacin treatment o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336246/ https://www.ncbi.nlm.nih.gov/pubmed/25705398 http://dx.doi.org/10.1186/2052-0492-1-3 |
_version_ | 1782358438201786368 |
---|---|
author | Iwashita, Yoshiaki Enokiya, Tomoyuki Suzuki, Kei Yokoyama, Kazuto Yamamoto, Akitaka Ishikura, Ken Okuda, Masahiro Imai, Hiroshi |
author_facet | Iwashita, Yoshiaki Enokiya, Tomoyuki Suzuki, Kei Yokoyama, Kazuto Yamamoto, Akitaka Ishikura, Ken Okuda, Masahiro Imai, Hiroshi |
author_sort | Iwashita, Yoshiaki |
collection | PubMed |
description | Treatment of infections caused by multidrug-resistant Pseudomonas species is difficult because few antibiotics active against such organisms are available. Arbekacin, a relatively new aminoglycoside, is effective against Pseudomonas spp. in vitro. However, no clinical report on arbekacin treatment of a human infection with a multidrug-resistant Pseudomonas has appeared to date. We encountered a case of pneumonia caused by a Pseudomonas strain producing a metallo-beta-lactamase; the patient was successfully treated with arbekacin. A 69-year-old male presented to our hospital experiencing cardiac arrest after rescue from water. Spontaneous circulation had earlier resumed after brief application of cardiopulmonary resuscitation. The patient was subjected to induced hypothermia. He experienced severe acute respiratory distress syndrome. The patient regained consciousness on day 8 post-admission. Episodes of ventilator-associated pneumonia were recorded on days 5 and 12. The causative organism was a strain of Pseudomonas putida that produced a metallo-beta-lactamase. Combination therapy with arbekacin and levofloxacin successfully resolved the pneumonia. The patient was transferred to another hospital on day 37 to undergo further rehabilitation. Strains of P. putida producing metallo-beta-lactamases have become more widespread in recent years. Colistin is traditionally the drug of last resort to treat infections with multidrug-resistant Pseudomonas. However, colistin use is associated with a very high frequency of adverse effects, and the costs of such therapy are not covered by the Japanese health insurance system. Our results indicate that arbekacin is an efficient alternative to multidrug-resistant Pseudomonas. |
format | Online Article Text |
id | pubmed-4336246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43362462015-02-22 Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase Iwashita, Yoshiaki Enokiya, Tomoyuki Suzuki, Kei Yokoyama, Kazuto Yamamoto, Akitaka Ishikura, Ken Okuda, Masahiro Imai, Hiroshi J Intensive Care Case Report Treatment of infections caused by multidrug-resistant Pseudomonas species is difficult because few antibiotics active against such organisms are available. Arbekacin, a relatively new aminoglycoside, is effective against Pseudomonas spp. in vitro. However, no clinical report on arbekacin treatment of a human infection with a multidrug-resistant Pseudomonas has appeared to date. We encountered a case of pneumonia caused by a Pseudomonas strain producing a metallo-beta-lactamase; the patient was successfully treated with arbekacin. A 69-year-old male presented to our hospital experiencing cardiac arrest after rescue from water. Spontaneous circulation had earlier resumed after brief application of cardiopulmonary resuscitation. The patient was subjected to induced hypothermia. He experienced severe acute respiratory distress syndrome. The patient regained consciousness on day 8 post-admission. Episodes of ventilator-associated pneumonia were recorded on days 5 and 12. The causative organism was a strain of Pseudomonas putida that produced a metallo-beta-lactamase. Combination therapy with arbekacin and levofloxacin successfully resolved the pneumonia. The patient was transferred to another hospital on day 37 to undergo further rehabilitation. Strains of P. putida producing metallo-beta-lactamases have become more widespread in recent years. Colistin is traditionally the drug of last resort to treat infections with multidrug-resistant Pseudomonas. However, colistin use is associated with a very high frequency of adverse effects, and the costs of such therapy are not covered by the Japanese health insurance system. Our results indicate that arbekacin is an efficient alternative to multidrug-resistant Pseudomonas. BioMed Central 2013-10-23 /pmc/articles/PMC4336246/ /pubmed/25705398 http://dx.doi.org/10.1186/2052-0492-1-3 Text en © Iwashita et al.; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Iwashita, Yoshiaki Enokiya, Tomoyuki Suzuki, Kei Yokoyama, Kazuto Yamamoto, Akitaka Ishikura, Ken Okuda, Masahiro Imai, Hiroshi Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title_full | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title_fullStr | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title_full_unstemmed | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title_short | Arbekacin treatment of a patient infected with a Pseudomonas putida producing a metallo-beta-lactamase |
title_sort | arbekacin treatment of a patient infected with a pseudomonas putida producing a metallo-beta-lactamase |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336246/ https://www.ncbi.nlm.nih.gov/pubmed/25705398 http://dx.doi.org/10.1186/2052-0492-1-3 |
work_keys_str_mv | AT iwashitayoshiaki arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT enokiyatomoyuki arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT suzukikei arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT yokoyamakazuto arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT yamamotoakitaka arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT ishikuraken arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT okudamasahiro arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase AT imaihiroshi arbekacintreatmentofapatientinfectedwithapseudomonasputidaproducingametallobetalactamase |